title: [Risk factors associated with ceftazidime-resistant Klebsiella pneumoniae infection].
abstract: BACKGROUND
  Risk factors associated with ceftazidime-resistant Klebsiella pneumoniae (CAZ-R Kp) infection may vary among hospitals and in the same hospital at different time points. Knowledge of these factors is required to establish suitable infection control programs.
  
  
  METHODS
  A case-control study was conducted to assess risk factors for CAZ-R Kp infection. Thirty-two cases were compared with 28 controls admitted to a 200-bed general hospital during 1999 and 2000.
  
  
  RESULTS
  In the univariate analysis Kp CAZ-R isolates were significantly associated with nosocomial acquisition (OR 5 17.40), prior antibiotic use (OR 5 14.94), particularly ciprofloxacin use (OR 5 5), and hospitalization stay of more than 6 days (OR 5 6.72). Significantly associated variables in the logistic regression analysis included nosocomial acquisition (OR 5 9.29), prior antibiotic use (OR 5 6.21), and particularly, ciprofloxacin use (OR 5 10.84).
  
  
  CONCLUSIONS
  Efforts toward more rational overall antibiotic use and particularly ciprofloxacin use, combined with infection control measures are necessary to decrease the prevalence of CAZ-R Kp in our hospital.
authors.affiliation: Unidad de Enfermedades Infecciosas. Hospital Español. Rosario. Argentina. jbermejo@infovia.com.ar
authors.forename: Joaquín
authors.initials: J
authors.lastname: Bermejo
authors.forename: Patricia
authors.initials: P
authors.lastname: Lesnaberes
authors.forename: Nora
authors.initials: N
authors.lastname: Arnesi
authors.forename: Mariano
authors.initials: M
authors.lastname: Gianello
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Notario
authors.forename: Noemí
authors.initials: N
authors.lastname: Borda
authors.forename: Telma
authors.initials: T
authors.lastname: Gambandé
authors.forename: Blanca
authors.initials: B
authors.lastname: Bencomo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001118:Argentina / Q000453:epidemiology; D001426:Bacterial Proteins / Q000235:genetics; D016022:Case-Control Studies; D002442:Ceftazidime / Q000494:pharmacology* / Q000627:therapeutic use; D018550:Cephalosporin Resistance / Q000235:genetics; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D004198:Disease Susceptibility; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D016867:Immunocompromised Host; D017053:Infection Control / Q000458:organization & administration; D007710:Klebsiella Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D007902:Length of Stay / Q000706:statistics & numerical data; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D015163:Superinfection; D001618:beta-Lactamases / Q000235:genetics
chemical_list: D001426:Bacterial Proteins; D002939:Ciprofloxacin; D002442:Ceftazidime; D001618:beta-Lactamases; C060181:beta-lactamase CAZ-1